Trial reportMolecular psychiatry2021
A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation.
Trial report in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- The impact of alcohol priming on craving and motivation to drink: a meta-analysis.Addiction (Abingdon, England) · 2022Pooled it
- Baclofen Modulates Neural Intrinsic Functional Connectivity in Treatment-Seeking Individuals With Alcohol Use Disorder.Alcohol, clinical & experimental research · 2026Trial
- Evaluation of glycine treatment for reducing alcohol craving and self-administration in individuals with alcohol use disorder: A human laboratory trial.Alcohol, clinical & experimental research · 2025Trial
- Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals.Psychopharmacology · 2021Trial
- A Case Report: Successful Management of Mixed Tardive Syndrome With Combination Pharmacotherapy in a 19-Year-Old Female With Schizophrenia.Clinical case reports · 2026Article
- Baclofen Promotes Osteochondrogenic Commitment of Mesenchymal Stem Cells: Implications for Heterotopic Ossification Risk.International journal of molecular sciences · 2026Article
- Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder.Alcohol, clinical & experimental research · 2026Article
- Bridging Genomics and Pharmacoepidemiology to Expand Treatment Options for Alcohol Use Disorder.medRxiv : the preprint server for health sciences · 2026Article
- GABAMedComm · 2025Review
- Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies.Clinics in liver disease · 2024Review
- Multi-modal neuroimaging reveals differences in alcohol-cue reactivity but not neurometabolite concentrations in adolescents who drink alcohol.Drug and alcohol dependence · 2024Article
- Trait sensitivity to positive feedback is a predisposing factor for several aspects of compulsive alcohol drinking in male rats: behavioural, physiological, and molecular correlates.Psychopharmacology · 2024Article
- Neuroimaging and neuroendocrine insights into food cravings and appetite interventions in obesity.Psychoradiology · 2023Review
- Sex-related differences in the efficacy of Baclofen enantiomers on self-administered alcohol in a binge drinking pattern and dopamine release in the core of the nucleus accumbens.Frontiers in pharmacology · 2023Article
- Neurosteroids (allopregnanolone) and alcohol use disorder: From mechanisms to potential pharmacotherapy.Pharmacology & therapeutics · 2022Review
- Review
- Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders.Current addiction reports · 2022Review
- Epigenetic Regulation of GABAergic Neurotransmission and Neurosteroid Biosynthesis in Alcohol Use Disorder.The international journal of neuropsychopharmacology · 2021Article
- Alcohol Tolerance in Human Laboratory Studies for Development of Medications to treat Alcohol Use Disorder.Alcohol and alcoholism (Oxford, Oxfordshire) · 2020Review
- Advances in the science and treatment of alcohol use disorder.Science advances · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Previous studies suggest that GABA-B receptor agonism may represent an effective pharmacological approach to treat addictive disorders. Baclofen is a selective GABA-B receptor agonist which has been investigated as a potential treatment for alcohol use disorder. However, research is needed to understand the biobehavioral mechanisms underlying baclofen's effect on alcohol use. In the present randomized, double-blind, placebo-controlled study, thirty-four alcohol-dependent individuals were randomized to receive baclofen (30 mg/d) or placebo for a week, and then participated in a laboratory experiment consisting of three procedures: alcohol cue-reactivity, priming, and self-administration. During the experiment, craving and other subjective responses to alcohol were assessed, and blood samples were collected for pharmacokinetic measurements. The effects of baclofen on the relationships between different alcohol-related laboratory parameters were investigated. Baclofen pharmacokinetic parameters and their correlations with behavioral measures were also examined. Results showed that baclofen disrupted the link between alcohol priming and self-administration, as indicated by significant interaction effects between drug condition (baclofen vs. placebo) and some of the priming variables (alcohol craving: F
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.